{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-001277","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2026-09-23T20:11:34+00:00","discovered_at":"2026-09-23T20:13:01.673016+00:00","generated_at":"2026-09-23T20:13:09.709771+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcturus reports positive ARCT-810 Phase 2 data, unveils LUNAR 2.0 platform, to acquire myNEO","bullets":["ARCT-810 generally safe; reduced/maintained fasting ammonia and glutamine in OTC deficiency patients.","LUNAR 2.0 shows 40-fold higher hEPO and 38-fold higher hOTC expression vs LUNAR 1.0 in NHP studies.","FDA feedback supports ARCT-2601 integration into ongoing Phase 2 study by year-end 2026.","Definitive agreement to acquire myNEO; closing expected in October 2026.","New programs for PKU and Gout announced using LUNAR 2.0."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-001277","json":"https://secwatch.observer/filing/0001193805-26-001277.json","markdown":"https://secwatch.observer/filing/0001193805-26-001277.md","text":"https://secwatch.observer/filing/0001193805-26-001277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/0001193805-26-001277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/e665798_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:13:09.709771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}